Lung Cancer Biomarkers
Pamela Villalobos1, Ignacio I Wistuba1
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 2130 Holcombe Boulevard, Unit 2951, Houston, TX 77030, USA.
Abstract:
The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it is possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has led to accelerated development of new drugs for lung cancer treatment. This article focuses on clinically relevant cancer biomarkers as targets for therapy and potential new targets for drug development.
Insights
Molecular lung cancer markers guide personalized therapy. Identifying biomarkers like EGFR mutations and ALK translocations enables targeted treatments and new drug development for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Molecular characterization is revolutionizing lung cancer diagnosis and treatment.
- Biomarkers like EGFR mutations and ALK translocations identify patients for targeted therapies.
Purpose of the Study:
- To review clinically relevant cancer biomarkers for lung cancer therapy.
- To discuss potential new biomarker targets for drug development.
Main Methods:
- Literature review of molecular lung cancer biomarkers.
- Analysis of targeted therapies and immunotherapies.
Main Results:
- Biomarker identification allows for personalized treatment strategies.
- Targeted therapies and immunotherapies have improved lung cancer outcomes.
Conclusions:
- Molecular biomarkers are crucial for personalized lung cancer treatment.
- Continued research into novel biomarkers will drive new drug development.
